Subtopic Deep Dive

G-Quadruplex Ligands Drug Design
Research Guide

What is G-Quadruplex Ligands Drug Design?

G-Quadruplex ligands drug design develops small molecules that selectively bind and stabilize G-quadruplex DNA structures to inhibit oncogene expression for cancer therapy.

Medicinal chemists design ligands including porphyrins, macrocycles, and metal complexes targeting G4 structures over duplex DNA. SAR studies link binding affinity to antiproliferative effects in oncogene promoters like MYC. Over 10 key papers since 2011 document ligand screening and optimization, with CX-5461 advancing to clinical trials (Xu et al., 2017, 567 citations).

Curated Papers

Key Challenges

Why It Matters

G4 ligands disrupt oncogene transcription, offering selective lethality in BRCA-deficient tumors as shown by CX-5461 (Xu et al., 2017). MYC downregulation via G4 stabilization suppresses lymphoma growth (Brown et al., 2011). Metal complexes provide anticancer potential through G4 targeting (Cao et al., 2016). These approaches enable precision oncology by exploiting G4 prevalence in promoter regions (Kosiol et al., 2021).

Key Research Challenges

G4 vs Duplex Selectivity

Ligands must discriminate G-quadruplex from duplex DNA to avoid off-target effects. Structural diversity of G4 topologies complicates selective binding (Bhattacharyya et al., 2016). Optimization requires balancing affinity and specificity (Cao et al., 2016).

Ligand Stability in Cells

Many ligands degrade or fail cellular uptake despite in vitro potency. Metal cation effects on G4 folding impact ligand efficacy (Bhattacharyya et al., 2016). Translation to in vivo models remains limited (Kosiol et al., 2021).

SAR-Antiproliferative Correlation

Linking binding constants to cellular activity demands integrated assays. MYC G4 ligands show variable downregulation (Brown et al., 2011). High-throughput screening for SAR needs better predictors (Calabrese et al., 2018).

Essential Papers

5'-UTR RNA G-quadruplexes: translation regulation and targeting

Anthony Bugaut, Shankar Balasubramanian · 2012 · Nucleic Acids Research · 635 citations

RNA structures in the untranslated regions (UTRs) of mRNAs influence post-transcriptional regulation of gene expression. Much of the knowledge in this area depends on canonical double-stranded RNA ...

Metal Cations in G-Quadruplex Folding and Stability

Debmalya Bhattacharyya, Gayan Mirihana Arachchilage, Soumitra Basu · 2016 · Frontiers in Chemistry · 612 citations

This review is focused on the structural and physicochemical aspects of metal cation coordination to G-Quadruplexes (GQ) and their effects on GQ stability and conformation. G-quadruplex structures ...

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours

Hong Xu, Marco Di Antonio, Steven McKinney et al. · 2017 · Nature Communications · 567 citations

G-quadruplexes: a promising target for cancer therapy

Nils Kosiol, Stefan Juranek, Peter Brossart et al. · 2021 · Molecular Cancer · 514 citations

Abstract DNA and RNA can fold into a variety of alternative conformations. In recent years, a particular nucleic acid structure was discussed to play a role in malignant transformation and cancer d...

G-quadruplex DNA targeted metal complexes acting as potential anticancer drugs

Qian Cao, Yi Li, E. Freisinger et al. · 2016 · Inorganic Chemistry Frontiers · 255 citations

This review summarizes the recent development of G4 DNA targeted metal complexes and discusses their potential as anticancer drugs.

Small Molecules Targeting c-Myc Oncogene: Promising Anti-Cancer Therapeutics

Bing-Jia Chen, Yanling Wu, Yoshimasa Tanaka et al. · 2014 · International Journal of Biological Sciences · 243 citations

The nuclear transcription factor c-Myc is a member of the Myc gene family with multiple functions and located on band q24.1 of chromosome 8. The c-Myc gene is activated by chromosomal translocation...

Demonstration that Drug-targeted Down-regulation of MYC in Non-Hodgkins Lymphoma Is Directly Mediated through the Promoter G-quadruplex

Robert V. Brown, Forest Danford, Vijay Gokhale et al. · 2011 · Journal of Biological Chemistry · 167 citations

Most transcription of the MYC proto-oncogene initiates in the near upstream promoter, within which lies the nuclease hypersensitive element (NHE) III(1) region containing the CT-element. This dynam...

Reading Guide

Foundational Papers

Start with Bugaut and Balasubramanian (2012, 635 citations) for RNA G4 regulation, Brown et al. (2011, 167 citations) for MYC targeting proof, Chen et al. (2014, 243 citations) for small molecule precedents.

Recent Advances

Study Xu et al. (2017, 567 citations) for clinical candidate CX-5461, Kosiol et al. (2021, 514 citations) for therapeutic overview, Calabrese et al. (2018, 166 citations) for MYC G4 recognition mechanisms.

Core Methods

FRET assays for stabilization (Xu et al., 2017), NMR/CD for binding modes (Calabrese et al., 2018), luminescence probes (He et al., 2013), metal coordination analysis (Bhattacharyya et al., 2016).

How PapersFlow Helps You Research G-Quadruplex Ligands Drug Design

Discover & Search

Research Agent uses searchPapers and exaSearch to find G4 ligand papers like 'CX-5461 is a DNA G-quadruplex stabilizer' (Xu et al., 2017), then citationGraph reveals 567 citing works on selectivity, while findSimilarPapers identifies metal complex analogs from Cao et al. (2016).

Analyze & Verify

Analysis Agent applies readPaperContent to extract SAR data from Calabrese et al. (2018), verifies binding claims with CoVe against Xu et al. (2017), and runs PythonAnalysis to plot Ki vs. IC50 correlations across 10 papers using NumPy/pandas, with GRADE scoring evidence strength for MYC downregulation.

Synthesize & Write

Synthesis Agent detects gaps in duplex selectivity studies via contradiction flagging across Bugaut et al. (2012) and Kosiol et al. (2021), while Writing Agent uses latexEditText, latexSyncCitations for 20 G4 papers, and latexCompile to generate drug design review manuscripts with exportMermaid for SAR flowcharts.

Use Cases

"Analyze Ki and IC50 data from MYC G4 ligand papers to model SAR."

Research Agent → searchPapers('MYC G-quadruplex ligands SAR') → Analysis Agent → readPaperContent(Brown 2011, Calabrese 2018) → runPythonAnalysis(pandas correlation plot, matplotlib scatter Ki vs IC50) → researcher gets CSV of fitted models and R² stats.

"Write LaTeX review on CX-5461 selectivity mechanisms."

Research Agent → citationGraph(Xu 2017) → Synthesis Agent → gap detection(duplex selectivity) → Writing Agent → latexEditText(structure), latexSyncCitations(15 papers), latexCompile(PDF) → researcher gets formatted review with auto-cited figures.

"Find code for G4 ligand docking simulations."

Research Agent → searchPapers('G-quadruplex ligand docking') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect(AutoDock scripts) → researcher gets validated GitHub repo with docking protocols for porphyrin optimization.

Automated Workflows

Deep Research workflow scans 50+ G4 ligand papers via searchPapers → citationGraph → structured report on SAR trends from Hurley/Balasubramanian works. DeepScan applies 7-step CoVe to verify CX-5461 claims (Xu et al., 2017) against metal complex data. Theorizer generates hypotheses on monovalent cation effects (Bhattacharyya et al., 2016) for novel ligand design.

Try Doxa for G-Quadruplex Ligands Drug Design Research

Frequently Asked Questions

What defines G-quadruplex ligands in drug design?

Small molecules, metal complexes, and porphyrins that selectively stabilize G4 DNA/RNA over duplex, targeting oncogene promoters like MYC (Brown et al., 2011).

What methods screen G4 ligands?

FRET melting assays, SPR for affinity, CD spectroscopy for topology, and cell-based antiproliferative tests; fluorogenic dyes aid detection (Bhasikuttan et al., 2015).

What are key papers on G4 ligands?

Xu et al. (2017, 567 citations) on CX-5461; Brown et al. (2011, 167 citations) on MYC G4; Cao et al. (2016, 255 citations) on metal complexes.

What open problems exist?

Achieving cellular stability, predicting selectivity from topology, correlating in vitro binding to in vivo efficacy (Kosiol et al., 2021; Bhattacharyya et al., 2016).